A 42-year-old man sustained a complete thoracic spinal cord transection three weeks ago. He presents for debridement of a sacral pressure ulcer. The anaesthetist must avoid suxamethonium. Which agent is the MOST appropriate alternative for rapid sequence induction?

Rocuronium at 1 to 1.2 mg/kg is the only non-depolarising neuromuscular blocking agent with an onset fast enough to substitute for suxamethonium in rapid sequence induction, while avoiding the lethal hyperkalemia that suxamethonium would trigger in a denervated patient.

Why rocuronium is the correct answer

The question presents two separate constraints that must both be satisfied. First, the patient has a complete thoracic spinal cord transection sustained three weeks ago. This makes suxamethonium absolutely contraindicated because of the risk of life-threatening hyperkalemia, discussed in detail in the next section. Second, the procedure is a debridement that requires general anaesthesia with rapid sequence induction, meaning the agent chosen must produce intubating conditions within 60 to 90 seconds, comparable to suxamethonium.

Among the non-depolarising neuromuscular blocking agents, onset speed is inversely related to potency. Rocuronium is the least potent aminosteroid agent, with an ED95 of 0.3 mg/kg, and this lower potency allows a larger number of molecules to be administered per kilogram of body weight. When the dose is escalated to 1 to 1.2 mg/kg (three to four times the ED95), rocuronium achieves excellent or good intubating conditions in approximately 60 seconds. No other non-depolarising agent in clinical use achieves this speed. Atracurium at 0.5 mg/kg and vecuronium at 0.1 mg/kg both require two to three minutes for adequate intubation conditions, which is too slow for a true rapid sequence. Mivacurium, even at 0.25 mg/kg, has an onset of roughly two minutes and is not used for rapid sequence induction.

The 1 to 1.2 mg/kg dose of rocuronium is the specific number that separates it from the other options in this question. This dose also produces a prolonged duration of action, approximately 70 to 80 minutes, which is acceptable for the surgical debridement but must be anticipated in the airway plan. The combination of rapid onset and avoidance of the suxamethonium-related hyperkalemic risk makes rocuronium the single best choice.

Denervation hypersensitivity and the suxamethonium danger

After a complete spinal cord transection, the lower motor neurons below the level of injury cease to provide neural input to the skeletal muscles they innervate. This denervation triggers a well-characterised molecular response: nicotinic acetylcholine receptors, which are normally confined to the neuromuscular junction, begin to proliferate across the entire muscle membrane. These extrajunctional receptors are structurally different from mature junctional receptors. They consist of the alpha-1, beta-1, delta, and gamma subunit composition (the fetal form) rather than the alpha-1, beta-1, delta, epsilon composition of the adult junctional receptor. The gamma subunit makes the channel open for a longer duration and increases the sensitivity to acetylcholine and to depolarising agents.

The timeline of this receptor proliferation is clinically critical. Extrajunctional receptors begin to appear at 48 to 72 hours after denervation, become widespread by two to three weeks, and persist for months to a year or more. The patient in this question is three weeks post-injury, placing him squarely in the window of maximal receptor proliferation. If suxamethonium is administered, the depolarising agent activates not only the normal junctional receptors but also the vast field of extrajunctional receptors across the entire muscle surface. This produces a massive, sustained efflux of potassium from the intracellular compartment into the extracellular space.

The resulting hyperkalemia can be severe enough to cause cardiac arrest. Serum potassium rises of 5 to 7 mEq/L have been reported after suxamethonium in denervated patients, compared to a rise of approximately 0.5 mEq/L in normal patients. The hyperkalemia can occur within minutes and may present as peaked T waves, loss of P waves, widened QRS complex, sine wave pattern, and ventricular fibrillation. This risk applies to any cause of denervation, including spinal cord injury, stroke with hemiplegia, burns after 48 to 72 hours, major trauma with prolonged immobilisation, and Guillain-Barre syndrome. The contraindication to suxamethonium persists for approximately one year after the injury, until the extrajunctional receptors regress.

Pharmacology of non-depolarising agents for rapid sequence induction

The fundamental principle governing onset time of non-depolarising neuromuscular blocking agents is that onset is inversely related to potency. A less potent drug requires a higher dose to achieve the same receptor occupancy, and the higher dose means more molecules are delivered to the neuromuscular junction per unit time. This larger concentration gradient drives faster diffusion to the postsynaptic receptors and produces a more rapid onset.

Rocuronium, with an ED95 of 0.3 mg/kg, is the least potent aminosteroid neuromuscular blocking agent. Vecuronium has an ED95 of 0.05 mg/kg, making it approximately six times more potent than rocuronium. Atracurium has an ED95 of 0.2 mg/kg. Mivacurium has an ED95 of 0.08 mg/kg. When each agent is given at its standard intubating dose, the number of effective doses administered determines the speed of onset.

The table below summarises the relevant pharmacology for rapid sequence induction.

Sugammadex is worth mentioning in this context. It is a modified gamma-cyclodextrin that encapsulates rocuronium and can reverse even profound rocuronium-induced neuromuscular blockade within three minutes. The availability of sugammadex has made high-dose rocuronium a more attractive option for rapid sequence induction because the prolonged duration of action can be rapidly reversed if intubation fails. This safety net does not exist for suxamethonium, whose duration is fixed by pseudocholinesterase metabolism.

Clinical application and perioperative considerations

When planning anaesthesia for a patient with recent spinal cord injury, the anaesthetist must address several issues beyond the choice of neuromuscular blocking agent. Autonomic hyperreflexia is a risk in injuries above T6, but this patient has a thoracic transection and the sacral debridement is below the level of injury, so the stimulus may not trigger the classic response. Nevertheless, adequate anaesthetic depth and avoidance of bladder distension remain important.

The patient is three weeks post-injury and likely has a flaccid paralysis below the lesion level, as he is still in spinal shock. The muscles below the transection are denervated and will respond to suxamethonium with exaggerated potassium release. The muscles above the transection remain innervated and would respond normally. However, the total potassium efflux from the large denervated muscle mass is sufficient to cause cardiac arrest, so the contraindication is absolute regardless of the proportion of denervated muscle.

Rocuronium at 1 to 1.2 mg/kg should be administered after adequate preoxygenation, with cricoid pressure applied, and the patient intubated at 60 seconds. The anaesthetist should confirm adequate neuromuscular blockade with a peripheral nerve stimulator before attempting laryngoscopy. The duration of action at this dose will be approximately 70 to 80 minutes, so the surgical team should be informed that reversal may be delayed. If sugammadex is available, 16 mg/kg can be administered for immediate reversal if needed.

Postoperatively, the patient should be monitored in a setting capable of managing potential respiratory depression, as the prolonged rocuronium effect may outlast the surgical procedure. The anaesthetic record should clearly document the contraindication to suxamethonium and the rationale for rocuronium use, as this patient will require future anaesthetics and the denervation hypersensitivity will persist for months.

Why the other options fail

One-glance recall table

Mnemonics

What the exam actually asks

• The 1 to 1.2 mg/kg dose of rocuronium is the specific number that exam questions test. Standard dose of 0.6 mg/kg is too slow for RSI.
• The 48 to 72 hour window for onset of extrajunctional receptors is frequently tested. Suxamethonium is safe in the first 24 hours after injury and dangerous from 48 to 72 hours onward.
• The contraindication to suxamethonium persists for approximately one year after denervation injury, not just the acute period.
• Burns, stroke with hemiplegia, Guillain-Barre syndrome, and major trauma with prolonged immobilisation all produce the same denervation hypersensitivity pattern as spinal cord injury.
• Sugammadex at 16 mg/kg can reverse even profound rocuronium blockade within three minutes, making high-dose rocuronium a safer RSI option than it was before sugammadex existed.

Traps that cost marks

• Assuming that any non-depolarising agent is an acceptable substitute for suxamethonium in rapid sequence induction. Only rocuronium at high dose has a fast enough onset.
• Believing that the suxamethonium contraindication applies only in the first 48 hours after injury. The danger begins at 48 to 72 hours and persists for months.
• Confusing mivacurium's short duration with a rapid onset. Short duration and rapid onset are pharmacologically distinct properties.
• Forgetting that the hyperkalemic response comes from the denervated muscle mass below the lesion, which is large enough to cause cardiac arrest even though the muscles above the lesion respond normally.

Frequently asked

Why is suxamethonium contraindicated after spinal cord injury?

After spinal cord injury, the denervated muscles below the lesion develop extrajunctional nicotinic receptors across the entire muscle membrane, beginning at 48 to 72 hours and persisting for months. Suxamethonium activates these widespread receptors, causing a massive potassium efflux that can produce serum potassium rises of 5 to 7 mEq/L and lead to cardiac arrest. The contraindication applies to all causes of denervation, including burns, stroke, and Guillain-Barre syndrome, and persists for approximately one year.

What is the correct dose of rocuronium for rapid sequence induction?

The correct dose is 1 to 1.2 mg/kg, which is three to four times the ED95. This high dose achieves excellent intubating conditions in approximately 60 seconds, comparable to suxamethonium. The standard intubating dose of 0.6 mg/kg has an onset of 90 to 120 seconds and is too slow for rapid sequence induction. The high dose produces a prolonged duration of action of approximately 70 to 80 minutes, which must be anticipated in the airway and recovery plan.

Can sugammadex reverse rocuronium used for rapid sequence induction?

Yes. Sugammadex at 16 mg/kg can reverse even profound rocuronium-induced neuromuscular blockade within three minutes of administration. This makes high-dose rocuronium a safer option for rapid sequence induction because the prolonged duration of action can be rapidly reversed if intubation fails or the procedure is shorter than expected. Sugammadex does not reverse suxamethonium, vecuronium as effectively, or mivacurium.

References

• Miller's Anesthesia, 9th. Neuromuscular blocking agents and denervation hypersensitivity
• Morgan and Mikhail's Clinical Anesthesiology, 6th. Pharmacology of neuromuscular blocking agents and rapid sequence induction
• Stoelting's Pharmacology and Physiology in Anesthetic Practice, 5th. Onset time and potency relationships of non-depolarising agents